Johnson & Johnson Pre-Tax Profit Margin 2010-2024 | JNJ
Current and historical pre-tax profit margin for Johnson & Johnson (JNJ) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Johnson & Johnson pre-tax profit margin for the three months ending September 30, 2024 was .
| Johnson & Johnson Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$87.70B |
$17.63B |
20.10% |
| 2024-06-30 |
$86.58B |
$19.51B |
22.53% |
| 2024-03-31 |
$85.65B |
$20.06B |
23.42% |
| 2023-12-31 |
$85.16B |
$15.06B |
17.69% |
| 2023-09-30 |
$76.31B |
$12.72B |
16.67% |
| 2023-06-30 |
$74.96B |
$12.68B |
16.91% |
| 2023-03-31 |
$77.46B |
$12.21B |
15.76% |
| 2022-12-31 |
$79.99B |
$19.36B |
24.20% |
| 2022-09-30 |
$77.21B |
$18.11B |
23.46% |
| 2022-06-30 |
$80.55B |
$16.79B |
20.84% |
| 2022-03-31 |
$79.85B |
$17.61B |
22.06% |
| 2021-12-31 |
$78.74B |
$19.18B |
24.36% |
| 2021-09-30 |
$91.45B |
$19.59B |
21.42% |
| 2021-06-30 |
$89.19B |
$20.14B |
22.58% |
| 2021-03-31 |
$84.21B |
$17.42B |
20.68% |
| 2020-12-31 |
$82.58B |
$16.50B |
19.98% |
| 2020-09-30 |
$80.86B |
$19.07B |
23.58% |
| 2020-06-30 |
$80.50B |
$16.31B |
20.27% |
| 2020-03-31 |
$82.73B |
$19.42B |
23.47% |
| 2019-12-31 |
$82.06B |
$17.33B |
21.12% |
| 2019-09-30 |
$81.71B |
$16.23B |
19.87% |
| 2019-06-30 |
$81.33B |
$19.01B |
23.37% |
| 2019-03-31 |
$81.59B |
$16.94B |
20.76% |
| 2018-12-31 |
$81.58B |
$18.00B |
22.06% |
| 2018-09-30 |
$81.38B |
$17.44B |
21.43% |
| 2018-06-30 |
$80.68B |
$17.80B |
22.07% |
| 2018-03-31 |
$78.69B |
$17.58B |
22.34% |
| 2017-12-31 |
$76.45B |
$17.67B |
23.12% |
| 2017-09-30 |
$74.36B |
$19.44B |
26.14% |
| 2017-06-30 |
$72.53B |
$19.93B |
27.48% |
| 2017-03-31 |
$72.17B |
$20.08B |
27.83% |
| 2016-12-31 |
$71.89B |
$19.80B |
27.55% |
| 2016-09-30 |
$71.60B |
$19.24B |
26.87% |
| 2016-06-30 |
$70.88B |
$18.08B |
25.51% |
| 2016-03-31 |
$70.18B |
$18.92B |
26.95% |
| 2015-12-31 |
$70.07B |
$19.20B |
27.39% |
| 2015-09-30 |
$70.52B |
$18.14B |
25.73% |
| 2015-06-30 |
$71.88B |
$20.83B |
28.98% |
| 2015-03-31 |
$73.59B |
$20.71B |
28.15% |
| 2014-12-31 |
$74.33B |
$20.56B |
27.66% |
| 2014-09-30 |
$74.43B |
$20.61B |
27.69% |
| 2014-06-30 |
$73.54B |
$17.47B |
23.75% |
| 2014-03-31 |
$71.92B |
$16.63B |
23.13% |
| 2013-12-31 |
$71.31B |
$15.47B |
21.69% |
| 2013-09-30 |
$70.52B |
$15.82B |
22.44% |
| 2013-06-30 |
$69.99B |
$15.75B |
22.50% |
| 2013-03-31 |
$68.59B |
$12.99B |
18.94% |
| 2012-12-31 |
$67.22B |
$13.78B |
20.49% |
| 2012-09-30 |
$65.92B |
$10.99B |
16.68% |
| 2012-06-30 |
$64.87B |
$11.51B |
17.74% |
| 2012-03-31 |
$65.00B |
$12.90B |
19.84% |
| 2011-12-31 |
$65.03B |
$12.36B |
19.01% |
| 2011-09-30 |
$64.42B |
$14.27B |
22.15% |
| 2011-06-30 |
$63.40B |
$14.38B |
22.68% |
| 2011-03-31 |
$62.13B |
$15.18B |
24.43% |
| 2010-12-31 |
$61.59B |
$16.95B |
27.52% |
| 2010-09-30 |
$62.49B |
$17.32B |
27.72% |
| 2010-06-30 |
$62.59B |
$17.35B |
27.72% |
| 2010-03-31 |
$62.50B |
$17.39B |
27.83% |
| 2009-12-31 |
$61.90B |
$15.76B |
25.45% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
